Clinical Trial Update: 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension [Phase 3]

View source ↗

Summary

Phase 3 open-label extension study of intepirdine (RVT-101) in Alzheimer's disease was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Intepirdine (invoked as intepirdine)

Snippet

Sponsor: Axovant Sciences Ltd. | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2020-04-17